
TRVI Stock Forecast & Price Target
TRVI Analyst Ratings
Bulls say
Trevi Therapeutics is poised to become a leader in the development and commercialization of Haduvio, an investigational therapy for chronic cough in a variety of indications. With a strong pipeline and promising clinical data, the company has the potential to capture a significant market share in the treatment of chronic cough. Additionally, the recent discontinuation of a competing therapy by GSK suggests that Haduvio has a strong chance of becoming a first-in-class and best-in-class therapy.
Bears say
Trevi Therapeutics is facing a bleak future as their drug Haduvio's strong IP may not be enough to protect them from generic versions due to its non-composition-of-matter protection. Despite outperforming in 2026 and providing guidance for a range of $2.40 to $2.80 for 2027 EPS, the share price is trading at 5.8x forward EPS, indicating a lack of confidence in the company's potential success. Additionally, while the CORAL study showed promising results, further trials will be needed to replicate them, raising concerns about the consistency of the drug's efficacy.
This aggregate rating is based on analysts' research of Trevi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TRVI Analyst Forecast & Price Prediction
Start investing in TRVI
Order type
Buy in
Order amount
Est. shares
0 shares